HomeCompareZYNE vs NNN

ZYNE vs NNN: Dividend Comparison 2026

ZYNE yields 153.85% · NNN yields 5.66%● Live data

vsPost on X →
After 10 years · $10,000 invested · DRIP enabled
🏆 ZYNE wins by $28.41M in total portfolio value
10 years
ZYNE
ZYNE
● Live price
153.85%
Share price
$1.30
Annual div
$2.00
5Y div CAGR
0%
Payout ratio
50%
After 10 yrs · $10,000 · DRIP
Portfolio value
$28.43M
Annual income
$12,477,713.99
Full ZYNE calculator →
NNN
NNN REIT Inc.
● Live price
5.66%
Share price
$42.03
Annual div
$2.38
5Y div CAGR
8.6%
Payout ratio
50%
After 10 yrs · $10,000 · DRIP
Portfolio value
$25.5K
Annual income
$2,622.67
Full NNN calculator →

Portfolio growth — ZYNE vs NNN

📍 ZYNE pulled ahead of the other in Year 1

Annual dividend income

🛡️

Recession Test — Did They Cut Dividends?

How each stock treated shareholders during the 3 biggest crises of the last 20 years

Crisis PeriodZYNENNN
2008–2009
GFC
— No data— No data
2020 Q1–Q2
COVID
— No data— No data
2022 Q4
Rate Hike
— No data— No data
Based on dividend payment history. "Increased" = dividend grew during crisis. "Maintained" = held within 3%. "Cut" = reduced by more than 3%.
📅

Dividend Calendar Overlap

Combined, ZYNE + NNN cover 0 of 12 monthsgood coverage

Jan
Feb
Mar
Apr
May
Jun
Jul
Aug
Sep
Oct
Nov
Dec
ZYNE pays
NNN pays
Both pay
Neither
💰

Tax Bracket Optimizer

Which stock is actually better after tax? Adjust your rate to find out.

ZYNE
Annual income on $10K today (after 15% tax)
$13,076.92/yr
After 10yr DRIP, annual income (after tax)
$10,606,056.89/yr
NNN
Annual income on $10K today (after 15% tax)
$481.32/yr
After 10yr DRIP, annual income (after tax)
$2,229.27/yr
At 15% tax rate, ZYNE beats the other by $10,603,827.62/year in after-tax income after 10 years on $10,000
⚖️

Lazy Portfolio Split Optimizer

What's the optimal mix of ZYNE + NNN for your $10,000?

ZYNE: 50%NNN: 50%
100% NNN50/50100% ZYNE
Portfolio after 10yr
$14.23M
Annual income
$6,240,168.33/yr
Blended yield
43.86%
📊

Analyst Conviction Gap

Where Wall Street is most bullish on NNN right now

ZYNE
Analyst Ratings
3
Buy
6
Hold
Consensus: Hold
Altman Z
-8.9
Piotroski
2/9
NNN
Analyst Ratings
10
Buy
15
Hold
4
Sell
Consensus: Hold
Price Target
$44.93
+6.9% upside vs current
Range: $43.00 — $48.50
Altman Z
1.1
Piotroski
5/9
Analyst ratings via FMP. Altman Z-Score: >3.0 safe, 1.81–3.0 grey zone, <1.81 distress. Piotroski: 7–9 strong, 0–3 weak.
🏛️

Copy Congress — What Are Politicians Buying?

Senate & House STOCK Act disclosures (last 90 days)

ZYNE buys
0
NNN buys
0
No recent congressional trades found for ZYNE or NNN in the last 90 days.
STOCK Act mandates disclosure within 45 days of transaction. Data via FMP.Full tracker →
MetricZYNENNN
Forward yield153.85%5.66%
Annual dividend / share$2.00$2.38
Payout ratio50%50%
1-year div growth0%0%
5-year div CAGR0%8.6%
Portfolio after 10y$28.43M$25.5K
Annual income after 10y$12,477,713.99$2,622.67
Total dividends collected$26.36M$13.7K
Payment frequencyquarterlyquarterly
SectorStockREIT
Analyst consensusHoldHold

Year-by-year: ZYNE vs NNN ($10,000, DRIP)

YearZYNE PortfolioZYNE Income/yrNNN PortfolioNNN Income/yrGap
1← crossover$26,085$15,384.62$10,735$614.96+$15.3KZYNE
2$65,415$37,504.84$11,572$708.43+$53.8KZYNE
3$157,896$87,902.04$12,531$819.53+$145.4KZYNE
4$367,242$198,293.18$13,633$952.29+$353.6KZYNE
5$823,976$431,026.91$14,909$1,111.84+$809.1KZYNE
6$1,785,476$903,821.11$16,392$1,304.77+$1.77MZYNE
7$3,740,825$1,830,365.98$18,129$1,539.52+$3.72MZYNE
8$7,586,679$3,583,996.66$20,173$1,827.08+$7.57MZYNE
9$14,910,849$6,793,102.33$22,597$2,181.81+$14.89MZYNE
10$28,432,323$12,477,713.99$25,491$2,622.67+$28.41MZYNE

ZYNE vs NNN: Complete Analysis 2026

ZYNEStock

Zynerba Pharmaceuticals, Inc. operates as a clinical stage specialty pharmaceutical company. The company focuses on developing pharmaceutically-produced transdermal cannabinoid therapies for rare and near-rare neuropsychiatric disorders. It is developing Zygel, a pharmaceutically-produced cannabidiol formulated as a permeation-enhanced gel for transdermal delivery. The company was formerly known as AllTranz, Inc. and changed its name to Zynerba Pharmaceuticals, Inc. in August 2014. Zynerba Pharmaceuticals, Inc. was incorporated in 2007 and is headquartered in Devon, Pennsylvania.

Full ZYNE Calculator →

NNNREIT

National Retail Properties invests primarily in high-quality retail properties subject generally to long-term, net leases. As of September 30, 2020, the company owned 3,114 properties in 48 states with a gross leasable area of approximately 32.4 million square feet and with a weighted average remaining lease term of 10.7 years.

Full NNN Calculator →
📬

Get this ZYNE vs NNN comparison by email

Save your analysis + weekly dividend insights. Free forever.

More comparisons

ZYNE vs SCHDZYNE vs JEPIZYNE vs OZYNE vs KOZYNE vs MAINZYNE vs ADCZYNE vs EPRTZYNE vs FCPT

⚠️ Educational purposes only. Not financial advice. Congressional trades sourced from SEC STOCK Act filings via FMP. Past performance does not guarantee future results.